Head-to-head evidence
ensifentrine vs TQC3721
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: PDE3/PDE4 · full Chronic Obstructive Pulmonary Disease pipeline
ensifentrine · Ohtuvayre
Marketed by Merck & Co. and partners
NCT04542057 · Phase 3 · completed
This was a large (790-patient), randomized, quadruple-blinded, placebo-controlled Phase 3 trial with a hard clinical/lung-function primary endpoint (change in FEV1 area under the curve over 12 hours), and the ensifentrine group showed a statistically significant improvement over placebo on that primary comparison. The randomization, blinding, active placebo control, adequate sample size, and clear statistically significant result in the favorable direction together support a strong grade.
Next expected readout: March 2027 · NCT05270525 (registry estimate)
TQC3721
Developed by Sino Biopharmaceutical
NCT06527144 · Phase 2 · completed
The trial randomized 240 participants to two TQC3721 doses or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinically relevant lung-function measure FEV1, but the registry does not report whether the comparison met its prespecified endpoint.
Next expected readout: February 2027 · NCT07464587 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ensifentrine's landscape · TQC3721's landscape